FTC Sets Conditions For $2.2B Hikma, Boehringer Deal
The Federal Trade Commission on Friday said that for Hikma Pharmaceuticals PLC's $2.2 billion purchase of Boehringer's U.S. generics business to pass antitrust muster, the drugmaker would have to sell all...To view the full article, register now.
Already a subscriber? Click here to view full article